Acrux Limited (AU:ACR) has released an update.
Acrux Limited, a specialty pharmaceutical company, has announced an amendment to their Quarterly Activities Report for March 2024, correcting the year to date column in their financial documents. The company has also reported a positive cash flow for the quarter and launched Dapsone Gel, 5% for acne vulgaris, marking their third revenue-generating product. With additional products under FDA review and plans for more, Acrux continues to expand its revenue base and product offerings.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.
